Fezolinetant is a neurokinin 3 (NK3) receptor antagonist.It is the first non-hormonal drug for hot flashes at menopause, and was approved by the United States Food and Drug Administration in May 2023 and Medicines and Healthcare Products Regulatory Agency (MHRA) of UK for moderate to severe vasomotor symptoms associated with menopause.
No takes yet. Share an insight, caveat, or question.
Ruchika Garg (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: